<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Problems of Virology</journal-id><journal-title-group><journal-title xml:lang="en">Problems of Virology</journal-title><trans-title-group xml:lang="ru"><trans-title>Вопросы вирусологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0507-4088</issn><issn publication-format="electronic">2411-2097</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11877</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Antiviral activity of human recombinant y-interferon and recombinant hybrid proteinof tumor necrosis factor-a-thymosin-сц on modelsof herpes-virus and cytomegalovirus infection invitro</article-title><trans-title-group xml:lang="ru"><trans-title>Противовирусная активность рекомбинантного интерферона-учеловека и рекомбинантного гибридного белка а-фактор некрозаопухолей-тимозин-oti на моделях герпес-вируснойи цитомегаловирусной инфекции in vitro</trans-title></trans-title-group></title-group><pub-date date-type="pub" iso-8601-date="2004-10-15" publication-format="electronic"><day>15</day><month>10</month><year>2004</year></pub-date><volume>49</volume><issue>5</issue><issue-title xml:lang="en">NO5 (2004)</issue-title><issue-title xml:lang="ru">№5 (2004)</issue-title><fpage>37</fpage><lpage>40</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2004, Barinsky I.F., Alimbarova L.M., Platonova A.A., Shmelev V.A.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2004, Баринский И.Ф., Алимбарова Л.М., Платонова А.А., Шмелев В.А.</copyright-statement><copyright-year>2004</copyright-year><copyright-holder xml:lang="en">Barinsky I.F., Alimbarova L.M., Platonova A.A., Shmelev V.A.</copyright-holder><copyright-holder xml:lang="ru">Баринский И.Ф., Алимбарова Л.М., Платонова А.А., Шмелев В.А.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://virusjour.crie.ru/jour/article/view/11877">https://virusjour.crie.ru/jour/article/view/11877</self-uri><abstract xml:lang="en"><p>The conducted studies showed a certain efficiency of gene-engineering preparation of IFN-y and TNF-T in virus
infections caused by herpes simplex virus 2 (HSV-2) and cytomegalovirus (CMV) in cell cultures of human embryo
fibroblast (HEF). The drugs have no viricidal action. IFN-y, when used according to the treatment scheme in vitro,
proved to be more effective versus TMF-T both in HSV-2 and in CMV. It inhibited significantly the HSV-2 reproduction within the dilution range of 1: 50 to 1 : 500. It was also effective, when used in CMV, within the dilution range
of 1 : 5000 and lower, whereas TNF-T was effective within the range of 1 : 500 and lower as well as in 0.1 multiple
infection. A significantly higher effect was ensured when the drugs were used for prevention. In HSV-2, IFN-y inhibited the virus reproduction, like in the treatment scheme, within the dilution range of 1 : 50 to 1 : 500, whereas
TNF-T was effective in the range of 1 : 50. In CMV, the drugs' effect, when used for prevention, was similar to that
observed in the treatment scheme. The highest inhibition values were registered for HSV-2, when it was used 24
hours before infection (IFN-y - 2.25 lg, dilution range of 1 : 50; TNF-2 -1.0 lg, dilution range of 1 : 50). IFN-y and
TNF-2 exert a synergic action on different stages of virus reproduction. A reliable additive effect was ensured in
prevention made 4 hour before infection by IFN-y and TNF-T only in experimental CMV infection.</p></abstract><trans-abstract xml:lang="ru"><p>Проведенные исследования показали определенную эффективность генно-инженерных препаратов ИФН-у и ФНО-Т при вирусных инфекциях, обусловленных ВПГ-2 и ЦМВ в культуре клеток ФЭЧ. Препараты ИФН-у и ФНО-Т не оказывают вирулицидного действия. При использовании по лечебной схеме in vitro препарат
ИФН-у оказался более эффективным, чем препарат ФНО-Т при инфекции как ВПГ-2, так и ЦМВ. Препарат
ИФН-у достоверно ингибировал репродукцию ВПГ-2 в диапазоне разведений от 1:50 до 1:500. При ЦМВ-инфекции по лечебной схеме применения ИФН-д оказался эффективным в разведениях 1:5000 и ниже, а
ФНО-Т - в разведении 1:500 и ниже при множественности инфицирования 0,1. Более значительный защитный эффект был получен при профилактическом использовании этих препаратов. При инфекции ВПГ-2 препарат ИФН-у ингибировал репродукцию вируса в разведениях 1:50-1:500, как и при лечебной схеме,
тогда как препарат ФНО-Т действовал в разведении 1:50. При ЦМВ-инфекции действие указанных препаратов по профилактической схеме оказалось аналогичным таковому при лечебной схеме. Наиболее высокие значения ингибирования ВПГ-2 отмечены при их использовании за 24 ч до инфицирования (2,25 lg
при применении препарата ИФН-у в разведении 1:50 и 1,0 lg при использовании препарата ФНО-Т в разведении 1:50). ИФН-у и ФНО-Т действуют синергично на различные этапы репродукции вирусов. Достоверный аддитивный эффект получен при профилактическом применении (за 4 ч до заражения) препаратов
ИФН-у и ФНО-Т только при экспериментальной ЦМВ-инфекции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>gamma-interferon</kwd><kwd>tumor necrosis factor</kwd><kwd>herpes simplex virus</kwd><kwd>cell culture</kwd><kwd>viricidal action</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гамма-интерферон</kwd><kwd>фактор некроза опухолей</kwd><kwd>вирус простого герпеса</kwd><kwd>цитомегаловирус</kwd><kwd>культура клеток</kwd><kwd>противовирусное действие</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Bach E. A., Aguet М., Schreiber R. D. The IFN gamma receptor: a paradigm for cytokine receptor signaling // Annu. Rev. Immunol. - 1997. - Vol. 15. - P. 563-591.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Baskin H., Ellermann-Eriksen S., Lovmand J., Mogensen S. C. Herpes simplex virus type 2 synergizes with interferon-gamma in the induction of nitric oxide production in mouse macrophages through autocrine secretion of tumour necrosis factoralpha//J. Gen. Virol. - 1997. - Vol. 78, Pt 1. - P. 195-203.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chen S. H., Okes J. E., Lausch R. N. Synergistic antherpes effect of TNF-alpha and IFN-gamma in human corneal epithelial cells compared with that in corneal fibroblasts // Antiviral Res. - 1994. - Vol. 25, N 3-4. - P. 201-213.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Costa-Pereira A. P., Williams Т. M., Strobl B. et al. The antiviral response to gamma interferon // J. Virol. - 2002. - Vol. 76, N 18. - P. 9060-9068.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Feduchi E., Alonso M. A., Carrasco L. Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus // J. Virol. - 1989. - Vol. 63, N 3. - P. 1354-1359.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Feduchi E., Carrasco L. Mechanism of inhibition of HSV-1 replication by tumor necrosis factr and interferon gamma // Virology. - 1991. - Vol. 180, N 2. - P. 822-825.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lee A. H., Hong J. H., Seo Y. S. Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors // Biochem. J. - 2000.	- Vol. 350, Pt 1. - P. 131-138.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Mestan J., Digel W., Mittnacht S. et al. Antiviral effects of recombinant tumour necrosis factor in vitro // Nature. - 1986. - Vol. 323, N 6091. - P. 816-819.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Presti R. M., Popkin D. L., Connick M. et al. Novel cell type-specific antiviral mechanism of interferon gamma action in macrophages // J. Exp. Med. - 2001. - Vol. 193, N 4. - P. 483-496.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Samuel С. Е. Antiviral actions of interferons // Clin. Microbiol. Rev. - 2001. - Vol. 14, N 4. - P. 778-809.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Sen G. C. Viruses and interferons // Annu. Rev. Microbiol. - 2001.	- Vol. 55. - P. 255-281.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Stark G. R., Kerr I. M., Williams B. R. et al. How cells respond to interferons // Annu. Rev. Biochem. - 1998. - Vol. 67. - P. 227-264.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Taylor J. L., Little S. D., O'Brien W. J. The comparative antiherpes simplex virus effects of human interferons // J. Interferon Cytokine Res. - 1998. - Vol. 18, N 3. - P. 159-165.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wong G. H., Goeddel D. V. Tumour ncrosis factors alpha and beta inhibit virus replication and synergize with interferons // Nature. - 1986. - Vol. 323, N 6091. - P. 819-822.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zhang H., Fu S., Busch A., Chen F. et al. Identification of TNF- alpha-sensitive sites in HCMViel promoter // Exp. Mol. Pathol. - 2001. - Vol. 71, N 2. - P. 106-114.</mixed-citation></ref></ref-list></back></article>
